MX2013014630A - Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. - Google Patents
Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.Info
- Publication number
- MX2013014630A MX2013014630A MX2013014630A MX2013014630A MX2013014630A MX 2013014630 A MX2013014630 A MX 2013014630A MX 2013014630 A MX2013014630 A MX 2013014630A MX 2013014630 A MX2013014630 A MX 2013014630A MX 2013014630 A MX2013014630 A MX 2013014630A
- Authority
- MX
- Mexico
- Prior art keywords
- leukotoxin
- microbicide
- inflammatory agent
- new anti
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
Abstract
La presente invención se refiere a métodos para prevenir o tratar la infección por el virus de inmunodeficiencia humana (VIH), afecciones inflamatorias y la enfermedad de injerto contra huésped (GVHD) en un sujeto. Las composiciones terapéuticas de la presente invención comprenden proteínas o polipéptidos de leucocidina E (LuKe) y/o D. La invención también referida a métodos para tratar infección por Staphylococcus aureus administrando una composición que comprende un antagonista de CCR5 o cualquier molécula que bloquea la interacción de LuKe/D con células CCR5' en una cantidad eficaz para tratar la infección por S. aureus en el sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498606P | 2011-06-19 | 2011-06-19 | |
PCT/US2012/043182 WO2012177660A2 (en) | 2011-06-19 | 2012-06-19 | Leukotoxin e/d as a new anti-inflammatory agent and microbicide |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014630A true MX2013014630A (es) | 2014-05-14 |
MX343589B MX343589B (es) | 2016-11-11 |
Family
ID=47423178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014630A MX343589B (es) | 2011-06-19 | 2012-06-19 | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. |
Country Status (14)
Country | Link |
---|---|
US (3) | US8846609B2 (es) |
EP (2) | EP2720754B1 (es) |
JP (1) | JP6093760B2 (es) |
KR (1) | KR20140071318A (es) |
CN (1) | CN103764228B (es) |
AU (1) | AU2012273125B2 (es) |
BR (1) | BR112013032911A2 (es) |
CA (1) | CA2839558A1 (es) |
CL (1) | CL2013003651A1 (es) |
ES (1) | ES2609817T3 (es) |
MX (1) | MX343589B (es) |
MY (1) | MY165115A (es) |
RU (1) | RU2609650C2 (es) |
WO (1) | WO2012177660A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX340446B (es) * | 2011-06-19 | 2016-07-08 | Univ New York | Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas. |
CA2871152A1 (en) | 2012-05-02 | 2013-11-07 | New York University | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
CN110420316A (zh) | 2013-06-18 | 2019-11-08 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点 |
CN104744451A (zh) * | 2013-12-30 | 2015-07-01 | 中国科学院上海药物研究所 | 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途 |
RU2017139800A (ru) * | 2015-04-17 | 2019-05-17 | Арсанис Байосайенсиз Гмбх | Комбинированный препарат антител против staphylococcus aureus |
CN107847514A (zh) * | 2015-06-23 | 2018-03-27 | 西托戴恩股份有限公司 | 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015238A1 (en) | 1998-09-14 | 2000-03-23 | Nabi | COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV |
US20070010509A1 (en) | 1999-12-08 | 2007-01-11 | Tatsuki Shiota | Cycloamine ccr5 receptor antagonists |
AU2001243145A1 (en) * | 2000-02-09 | 2001-08-20 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
US6476062B2 (en) | 2000-03-30 | 2002-11-05 | Schering Corporation | Chemokine receptor antagonists |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
US20030171563A1 (en) | 2001-05-18 | 2003-09-11 | Mcnamara Peter J. | Regulators of bacterial virulence factor expression |
MXPA05000081A (es) | 2002-06-27 | 2005-04-11 | Schering Ag | Quinolinas sustituidas antagonistas del receptor ccr5. |
US7288654B2 (en) * | 2003-02-07 | 2007-10-30 | Takeda Pharmaceutical Company Ltd | Fused-ring pyridine derivative, process for producing the same, and use |
IL157398A0 (en) * | 2003-08-14 | 2004-02-19 | Hadasit Med Res Service | Pharmaceutical compositions comprising ccr5 antagonists |
US7622125B2 (en) * | 2004-05-05 | 2009-11-24 | Novartis Vaccines And Diagnostics, Inc. | Polycistronic HIV vector constructs |
KR101359930B1 (ko) | 2004-09-22 | 2014-02-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성조성물 |
DE602006017507D1 (de) | 2005-01-06 | 2010-11-25 | Schering Corp | Synthese von ccr5 rezeptor antagonisten |
WO2007062150A2 (en) | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Leukotoxin compositions and therapeutic methods |
WO2007095347A2 (en) * | 2006-02-13 | 2007-08-23 | The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods and compositions related to ghs-r antagonists |
US20090247570A1 (en) * | 2006-06-12 | 2009-10-01 | Pfizer Inc | Pharmaceuticals |
CA2655133C (en) * | 2006-06-12 | 2018-03-20 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
JP2008013447A (ja) | 2006-07-03 | 2008-01-24 | Juntendo | 毒素検出方法 |
JP5245827B2 (ja) * | 2006-07-31 | 2013-07-24 | 小野薬品工業株式会社 | スピロ結合した環状基を含有する化合物およびその用途 |
CA2662835A1 (en) | 2006-09-18 | 2008-03-27 | Remy Lemoine | Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents |
WO2008099278A2 (en) * | 2007-02-15 | 2008-08-21 | Pfizer Limited | Pharmaceutical compositions and methods for ccr5 antagonists |
NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
US8409584B2 (en) | 2009-05-05 | 2013-04-02 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
EP2488198B1 (en) | 2009-10-13 | 2016-09-28 | Rutgers, the State University of New Jersey | Treatment and diagnosis of autoimmune disorders |
-
2012
- 2012-06-19 KR KR20147000899A patent/KR20140071318A/ko not_active Application Discontinuation
- 2012-06-19 JP JP2014517101A patent/JP6093760B2/ja not_active Expired - Fee Related
- 2012-06-19 MX MX2013014630A patent/MX343589B/es active IP Right Grant
- 2012-06-19 MY MYPI2013004568A patent/MY165115A/en unknown
- 2012-06-19 AU AU2012273125A patent/AU2012273125B2/en not_active Ceased
- 2012-06-19 CA CA 2839558 patent/CA2839558A1/en not_active Abandoned
- 2012-06-19 RU RU2014101489A patent/RU2609650C2/ru not_active IP Right Cessation
- 2012-06-19 BR BR112013032911A patent/BR112013032911A2/pt not_active IP Right Cessation
- 2012-06-19 ES ES12802525.1T patent/ES2609817T3/es active Active
- 2012-06-19 EP EP12802525.1A patent/EP2720754B1/en not_active Not-in-force
- 2012-06-19 WO PCT/US2012/043182 patent/WO2012177660A2/en active Application Filing
- 2012-06-19 EP EP16187708.9A patent/EP3135339A1/en not_active Withdrawn
- 2012-06-19 CN CN201280039369.2A patent/CN103764228B/zh not_active Expired - Fee Related
- 2012-06-19 US US13/527,438 patent/US8846609B2/en active Active
-
2013
- 2013-12-19 CL CL2013003651A patent/CL2013003651A1/es unknown
-
2014
- 2014-08-25 US US14/468,026 patent/US9480726B2/en not_active Expired - Fee Related
-
2016
- 2016-09-23 US US15/273,888 patent/US20170224768A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MY165115A (en) | 2018-02-28 |
EP2720754B1 (en) | 2016-10-19 |
WO2012177660A3 (en) | 2013-02-21 |
US8846609B2 (en) | 2014-09-30 |
WO2012177660A2 (en) | 2012-12-27 |
US20150056163A1 (en) | 2015-02-26 |
US20130039885A1 (en) | 2013-02-14 |
US20170224768A1 (en) | 2017-08-10 |
NZ619942A (en) | 2016-02-26 |
JP6093760B2 (ja) | 2017-03-08 |
CL2013003651A1 (es) | 2014-09-26 |
US9480726B2 (en) | 2016-11-01 |
AU2012273125B2 (en) | 2017-05-25 |
AU2012273125A1 (en) | 2014-01-16 |
KR20140071318A (ko) | 2014-06-11 |
BR112013032911A2 (pt) | 2017-01-24 |
JP2014520150A (ja) | 2014-08-21 |
MX343589B (es) | 2016-11-11 |
RU2014101489A (ru) | 2015-07-27 |
CN103764228A (zh) | 2014-04-30 |
RU2609650C2 (ru) | 2017-02-02 |
CA2839558A1 (en) | 2012-12-27 |
EP2720754A4 (en) | 2015-04-29 |
CN103764228B (zh) | 2017-09-08 |
EP3135339A1 (en) | 2017-03-01 |
EP2720754A2 (en) | 2014-04-23 |
ES2609817T3 (es) | 2017-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590342A1 (ru) | Лечение иммуноопосредуемых и воспалительных заболеваний | |
PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12014502524A1 (en) | Carboxylic acid compounds | |
PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
EA201500582A1 (ru) | Тройные фунгицидные смеси | |
CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MX2013011922A (es) | Compuestos de benceno substituido. | |
MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
GB2511685A (en) | Muscarinic m1 receptor agonists | |
MX343589B (es) | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. | |
MX2013004061A (es) | Analogos de ciclosporina. | |
EA201492016A1 (ru) | C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич | |
MX2013004062A (es) | Analogos de ciclosporina. | |
MX2015007065A (es) | Metodo y composiciones para tratar diarrea asociada con vih. | |
WO2014205127A3 (en) | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
IN2013MU01250A (es) | ||
IN2013MU01248A (es) | ||
IN2013MU01244A (es) | ||
IN2013MU01247A (es) | ||
IN2013MU01245A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |